Last reviewed · How we verify
A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of fully human anti-VEGFR2 monoclonal antibody, HLX06, in patients with advanced or metastatic tumors refractory to standard therapy. This study will also evaluate the pharmacokinetics, pharmacodynamics, immunogenicity and anti-tumor effect of HLX06 and explore the potential prognostic and predictive biomarkers.
Details
| Lead sponsor | Henlix, Inc |
|---|---|
| Phase | PHASE1 |
| Status | TERMINATED |
| Enrolment | 5 |
| Start date | Thu Mar 22 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Thu May 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Solid Tumor, Adult
Interventions
- HLX06
Countries
Taiwan